inclusion criteria: * written informed consent by the study participant or their legally appointed representative. * age ≥ 18 years * evidence of acute sars-cov-2 infection, confirmed by pcr testing * invasive ventilation * fever ≥ 38.5°c, confirmed by a total of 3 consecutive measurements or ongoing renal replacement therapy and temperature ≥ 37.5°c * d-dimers ≥ 2mg/l * dexamethasone ≥ 6mg/day or equivalent dose on at least 2 days

inclusion criteria: * written informed consent by the study participant or their legally appointed representative. * age ≥ 18 years * evidence of acute sars-cov-2 infection, confirmed by pcr testing * invasive ventilation * fever ≥ 38.5°c, confirmed by a total of 3 consecutive measurements or ongoing renal replacement therapy and temperature ≥ 37.5°c * d-dimers ≥ 2mg/l * dexamethasone ≥ 6mg/day or equivalent dose on at least 2 days

inclusion criteria: - written informed consent by the study participant or their legally appointed representative. - age ≥ 18 years - evidence of acute sars-cov-2 infection, confirmed by pcr testing - invasive ventilation - fever ≥ 38.5°c, confirmed by a total of 3 consecutive measurements or ongoing renal replacement therapy and temperature ≥ 37.5°c - d-dimers ≥ 2mg/l - dexamethasone ≥ 6mg/day or equivalent dose on at least 2 days

inclusion criteria: - written informed consent by the study participant or their legally appointed representative. - age ≥ 18 years - evidence of acute sars-cov-2 infection, confirmed by pcr testing - invasive ventilation - fever ≥ 38.5°c, confirmed by a total of 3 consecutive measurements or ongoing renal replacement therapy and temperature ≥ 37.5°c - d-dimers ≥ 2mg/l - dexamethasone ≥ 6mg/day or equivalent dose on at least 2 days

inclusion criteria: - written informed consent by the study participant or their legally appointed representative. - age ≥ 18 years - evidence of acute sars-cov-2 infection, confirmed by pcr testing - invasive ventilation - fever ≥ 38.5°c, confirmed by a total of 3 consecutive measurements or ongoing renal replacement therapy - d-dimers ≥ 2mg/l - dexamethasone ≥ 6mg/day or equivalent dose on at least 2 days

inclusion criteria: - written informed consent by the study participant or their legally appointed representative. - age ≥ 18 years - evidence of acute sars-cov-2 infection, confirmed by pcr testing - invasive ventilation - fever ≥ 38.5°c, confirmed by a total of 3 consecutive measurements or ongoing renal replacement therapy - d-dimers ≥ 2mg/l - dexamethasone ≥ 6mg/day or equivalent dose on at least 2 days

inclusion criteria: - written informed consent by the study participant or their legally appointed representative. - age ≥ 18 years - evidence of acute sars-cov-2 infection, confirmed by pcr testing - invasive ventilation - fever ≥ 38.5°c, confirmed by a total of 3 consecutive measurements - d-dimers ≥ 2mg/l - dexamethasone ≥ 6mg/day or equivalent dose on at least 2 days

inclusion criteria: - written informed consent by the study participant or their legally appointed representative. - age ≥ 18 years - evidence of acute sars-cov-2 infection, confirmed by pcr testing - invasive ventilation - fever ≥ 38.5°c, confirmed by a total of 3 consecutive measurements - d-dimers ≥ 2mg/l - dexamethasone ≥ 6mg/day or equivalent dose on at least 2 days